Clinical analysis on 28 cases of head-neck malignant fibrous histiocytoma.
- Author:
Xin LIN
1
;
Shaowen ZENG
;
Chu YANG
;
Chuangwei LI
;
Dongtao YANG
Author Information
1. Department of Otorhinolaryngology-Head and Neck Surgery, Shantou Central Hospital, the Affiliated Shantou Hospital of Sun Yat-sen University, Shantou, 515031, China. lxlx2205@163.com
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Female;
Head and Neck Neoplasms;
diagnosis;
surgery;
Histiocytoma, Malignant Fibrous;
diagnosis;
surgery;
Humans;
Male;
Middle Aged;
Retrospective Studies;
Young Adult
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2009;23(19):886-893
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the clinical feature and treatment of head-neck malignant fibrous histiocytoma (MFH).
METHOD:A retrospective analysis on the clinical data of 28 cases of MFH were carried out, of which 9 were in the maxilla, 3 in the nasal cavity, 5 in the larynx, 3 in the parotid, 3 in the temporal bone, 1 in the hypothyroid, and 4 in the head and neck region. All of the cases underwent immune histochemistry: 4 cases of surgery alone, 23 cases of surgery followed by radiotherapy, and 1 case of radiotherapy alone.
RESULT:Except 5 cases lost follow-up after 1 year, all the other cases were followed-up over 3 years, the survival rate for 1 or 3 years was respectively 96.4% (27/28) and 57.1% (16/28); 23 cases were followed up for 5 years, the survival rate was 26.1% (6/23). The recurrent rate in 3 years was 60.7% (17/28), with 1 to 7 times recurrence at a mean interval of 5.6 months. Twelve recurrent cases were adopted expanded resection of non-defined operation except 1 case with radiotherapy.
CONCLUSION:The diagnosis of MFH depends on the technology of immune histochemistry. Early diagnosis, expanded resection, and integrated therapy could reduce the recurrence and increase the survival rate; the recurrence could adopt expanded resection of non-defined operation to prolong the life.
